Company intelligence / Profile preview

CNNC Accuray Medical Technology

Tianjin, Tianjin, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

The Tomo C Radiation Treatment Delivery System, produced by CNNC Accuray, is a helical radiotherapy platform designed for precise cancer treatments; first approved in China in 2023 and successfully used to treat 100 patients in its launch hospital, supporting a broad range of cancer types and demonstrating rapid treatment capability and clinical impact[4][6][7].

Therapeutic areas: HematologyOncology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Accuray (joint venture partner)

Beyond the preview

Go deeper on CNNC Accuray Medical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNNC Accuray Medical Technology.

Explore the full profile